Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Cholecalciferol vitamin D 3
Magnesium Glycinate
: Vitamin D 60000 IU Single Dose + Magnesium Glycinate 250mg BD for 14 days
Sponsors
Suraksha Pharma Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex, 20 to 60 years of age with mild â?? moderate COVID -19 infection , found positive for COVID -19 test by RT_PCR are requiring Clinical management ( symptomatic patients who present with cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, insomnia, ageusia or alternative signs of respiratory infections.) 2. Participants who are willing to provide inform consent and willing to come for schedule follow up visit. 3. Participants who are having normal hematological renal hepatic Parameters 4. Participant not having contra indication to take standard treatment Vitamin D, magnesium 5. Participants tested positive for COVID 19 by nose throat swab using PCR technique 6. Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study.
Exclusion criteria
Exclusion criteria: 1. Patient having severe COVID -19 infection 2. Patients presenting severe respiratory and/or multi systemic symptoms compatible with advanced COVID-19 and inter current acute or severe chronic diseases (i.e. active cancer). 3. Participants with hypersensitivity or intolerance or contraindication to the use of standard treatment 4. Participants with known allergy or contraindication to Vitamin D, Magnesium 5. History of having received any investigational drug in the preceding one month. 6. History of taking any kind of formulation or any other form of therapy for COVID 19 prophylaxis . 7. Unwilling to come for regular follow-up for the entire duration of the study. 8. COVID -19 RT-PCR Negative 9. Any condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study. 10. Participants participating in other clinical study. 11. Participant receiving other immune enhancers. 12. Refusal to sign informed consent form 13. Symptomatic for sever COVID-19 infection needing ICU 14. Atherosclerotic Coronary Artery Disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative RT- PCR test for COVID 19 infection 2 Improvement in Signs and symptoms of COVID 19 infection, use of ventilator, length of stay in ICU 3 Reduction in CRP levels 4 Reduction in rate of COVID -19 complication . 5 Speed of recovery and duration to becoming asymptomatic 6 Length of hospital stay Timepoint: COVID 19 RT-PCR Test in 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the safety and efficacy of Vitamin D ( Cholecalciferol ) , with Magnesium in mild to moderate COVID- 19 patients Timepoint: 3 weeks | — |
Countries
India
Contacts
Public ContactAVN Sridhar
suraksha pharma
Outcome results
None listed